Quest Diagnostics to Develop Multi-cancer Stratification Blood Test Based on MD Anderson Technology (newsroom.questdiagnostics.com)

• Quest Diagnostics licenses MCaST technology for multi-cancer risk stratification
• Test uses protein biomarkers for nine cancer types
• Planned North America launch in 2026

"Quest Diagnostics announced a collaboration with MD Anderson Cancer Center to develop a blood test for cancer risk stratification. The test uses circulating protein biomarkers identified by Dr. Samir Hanash's lab, covering nine cancer types. Quest will license and refine the MCaST technology, aiming for North American availability in 2026 as a supplement to standard screenings, not a replacement."